PURPOSE:
• Research Question(s): o (i) to compare a current "standard of care" antibiotic, cephalexin, to placebo after surgical incision and drainage of uncomplicated skin abscesses o (ii) to establish the prevalence of MRSA in the population under study o (iii) to prospectively determine whether discordance between therapy and isolate susceptibility affected outcome
• Hypothesis: Empirical use of beta-lactam antibiotics, the preferred agents for treating uncomplicated skin and soft tissue infections, may no longer be appropriate for these infections because of the increasing prevalence of community strains of MRSA
DESIGN:
• Study Design: Randomized, Double-Blind, Placebo-Controlled Trial o Attrition: 4 total enrollees (2 from each group) were lost to follow-up
METHODS:
• Interventions: All enrollees underwent I+D of abscess by an attending surgeon, culture samples collected, wick placed or wound packed after drainage for healing by secondary intention, daily follow-up in clinic for wound check and bandage changes, and day-7 follow-up evaluation to evaluate for clinical outcome.
• Study Groups: Study group received Cephalexin 500mg PO QID x 7 days, Control Group received placebo PO QID x 7 days.
• Instruments:
• Data Collection: Data was collected by attending surgeon and nurse practitioners in the surgical clinic.
DATA ANALYSIS:
• Level of Data/Statistics Used: Dichotomous variables were analyzed using Fisher's exact test. Ordinal variables were analyzed using the Krushkal-Wallis test. Continuous variables were analyzed with Mann-Whitney tests.
• What, if any, variables were controlled for?: Patients who did not return for follow up, who could not be contacted by phone, and whose outcome could not be determined from chart review were deemed failures.
RESULTS:
• Brief answers to research questions: o (i) to compare a current "standard of care" antibiotic, cephalexin, to placebo after surgical incision and drainage of uncomplicated skin abscesses  Cephalexin (84% cure rate)  Placebo (90% cure rate) o (ii) to establish the prevalence of MRSA in the population under study  50% prevalence o (iii) to prospectively determine whether discordance between therapy and isolate susceptibility affected outcome  No effect on outcome o This study indicates that cephalexin does not have a significant benefit in addition to incision and drainage for uncomplicated skin abscesses.
• Additional findings: o Subgroup analysis of demographics, co-morbidities, abscess characteristics -data not powered to find significant differences between groups, though data suggests that these groups would not change overall trend in results/outcomes 
IMPLICATIONS FOR PRACTICE:
• Applicable to this clinical practice: The study population shares some similarities to our patient population, however not directly generalizable to ED patients in Portland Maine.
• Feasible (cost, resources, etc) : I+D instruments are inexpensive, expertise is readily available in the ED. Antibiotic administration after I+D in the ED is a relatively low cost (and routine) practice for some providers.
• Clinically Relevant: Yes
LEVEL OF EVIDENCE / DECISION FOR USE:
• Background X Consider Replication Ready for use
• Level of Evidence: Ia Evidence obtained from meta-analysis of randomized controlled trials X Ib Evidence obtained from at least one RCT IIa Evidence obtained from at least one well-designed controlled study without randomization IIb Evidence obtained from at least one other type of well-designed quasiexperimental study III Well-designed non-experimental studies IV Expert committee reports, opinions of experts
